Episode 113: ASCO 2024 - Metastatic Colorectal Cancer

Our 2024 ASCO epic trundles onto its next generation, advanced colorectal cancer. Over the last 10 years, treatment in this area has made incremental progress through the discovery of the clinically meaningful KRAS and BRAF mutation pathways and most recently with the potential for immunotherapy in the deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) subgroups. In this episode, Josh and Michael examine studies looking at KRAS G12C-mutated, HER2-positive and dMMR colorectal cancer, as well as a very exciting study examining the utility of transplantation in patients with liver-only colorectal metastases.

Links to studies discussed in this episode (subscription may be required):

CODEBREAK300: https://meetings.asco.org/2024-asco-annual-meeting/15829?presentation=234200%23234200 

MOUNTAINEER: https://meetings.asco.org/2024-asco-annual-meeting/15829?presentation=231646%23231646  

CHECKMATE 8HW: https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231645%23231645

TRANSMET: https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231641%23231641